Quoin Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Quoin Pharmaceuticals (QNRX).

Price Target Range — 4 Quarters

Analyst Consensus — 5 Analysts

5Buy

Consensus RatingBuy# Analysts5Avg. Consensus PT$21Upside to Avg. PT+429.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 19, 2026	Canaccord Genuity	Whitney Ijem	Initiate	Buy	$18
Oct 12, 2026	BTIG	Jeet Mukherjee	Initiate	Buy	$14
Sep 23, 2026	Lake Street	Thomas Flaten	Initiate	Buy	$20
May 4, 2026	LUCID CAPITAL MARKETS	Dev Prasad	Initiate	Buy	$30
Mar 15, 2024	Maxim Group	Naz Rahman	PT Cut	Buy	$525→$140

Analyst Ratings News

PRO
Canaccord Genuity Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $18

Canaccord Genuity analyst Whitney Ijem initiates coverage on Quoin Pharmaceuticals (NASDAQ:QNRX) with a Buy rating and announces Price Target of $18.

Benzinga Newsdesk

This Robinhood Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Analysts initiated coverage on ASBH, QNRX, AXGN and HOOD with bullish ratings and targets; IDXX received a Sector Weight rating.

Avi Kapoor

PRO
BTIG Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $14

BTIG analyst Jeet Mukherjee initiates coverage on Quoin Pharmaceuticals (NASDAQ:QNRX) with a Buy rating and announces Price Target of $14.

Benzinga Newsdesk

PRO
Lake Street Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $20

Lake Street analyst Thomas Flaten initiates coverage on Quoin Pharmaceuticals (NASDAQ:QNRX) with a Buy rating and announces Price Target of $20.

Benzinga Newsdesk

PRO
LUCID CAPITAL MARKETS Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $30

LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Quoin Pharmaceuticals (NASDAQ:QNRX) with a Buy rating and announces Price Target of $30.

Benzinga Newsdesk

Maxim Group Maintains Buy Rating for Quoin Pharmaceuticals: Here's What You Need To Know

Benzinga Insights

Quoin Pharmaceuticals Ltd

뉴스

파트너 / 기고자

벤징가 글로벌

Quoin Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Canaccord Genuity Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $18

This Robinhood Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

PRO
BTIG Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $14

PRO
Lake Street Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $20

PRO
LUCID CAPITAL MARKETS Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $30

Maxim Group Maintains Buy Rating for Quoin Pharmaceuticals: Here's What You Need To Know

People Also Watch

People Also Watch

Quoin Pharmaceuticals Ltd

뉴스

파트너 / 기고자

벤징가 글로벌

Quoin Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROCanaccord Genuity Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $18

This Robinhood Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

PROBTIG Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $14

PROLake Street Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $20

PROLUCID CAPITAL MARKETS Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $30

Maxim Group Maintains Buy Rating for Quoin Pharmaceuticals: Here's What You Need To Know

People Also Watch

People Also Watch

PRO
Canaccord Genuity Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $18

PRO
BTIG Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $14

PRO
Lake Street Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $20

PRO
LUCID CAPITAL MARKETS Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $30